AUTH/2009/6/07: Anonymous v Flynn Pharma — Promotion of Medikinet (No breach)

📅 2007 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/2009/6/07
PartiesAnonymous complainant v Flynn Pharma Ltd
ProductMedikinet / Medikinet XL (controlled release methylphenidate)
Therapy areaAttention deficit hyperactivity disorder (ADHD)
Main issues allegedInappropriate targeting of mailings/invitation; rep call requesting appointment; D&T application form provided by rep; German clinical paper with no English translation
Clauses considered12.1 and 15.3
DecisionNo breach of Clauses 12.1 and 15.3
Panel notesMailing to child psychiatrists and paediatricians not unreasonable; no evidence of inducement; German reference “not helpful” and English translation should have been provided if substantiation requested
Complaint received7 June 2007
Case completed4 July 2007
Applicable Code year2006
AppealNo appeal

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • An anonymous complainant said they received Flynn Pharma promotional mailings about Medikinet/Medikinet XL (ADHD) despite stating they did not and had never treated ADHD.
  • The mailing included a reply paid card (RPC); the complainant said it did not state anything about having to grant a representative an appointment.
  • A representative telephoned requesting an appointment.
  • A colleague allegedly received a drug and therapeutics (D&T) committee application form from a representative; the complainant believed such forms should not be handed out by representatives.
  • The colleague was also given a clinical paper in German (Döpfner et al) and told there was no English translation.
  • The complainant was invited to a meeting and considered this inappropriate given they did not treat ADHD; they asked the company to be more specific with targeting.
⚖️

Outcome

  • No breach of the Code was ruled.
  • No breach of Clause 12.1 (targeting/distribution of promotional material) — mailing to child psychiatrists and paediatricians was not unreasonable.
  • No breach of Clause 15.3 (inducements) — no evidence of inducement/subterfuge or repeated attempts to secure an interview.
  • Panel expressed a concern that providing only a German reference was “not helpful” and said an English translation should have been provided if substantiation had been requested; Panel asked that Flynn be advised of its concerns.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training